NCT01945294View on ClinicalTrials.gov

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

October 10, 2013

Primary Completion Date

August 5, 2015

Study Completion Date

November 4, 2015

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Boceprevir

800 mg three times daily orally

BIOLOGICAL

Peg-interferon alfa-2b

1.5 mcg/kg weekly subcutaneously

DRUG

Ribavirin

800-1400 mg twice-daily divided orally based on body weight

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01945294 - Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) | Biotech Hunter | Biotech Hunter